third generation glp 1 Next-Generation Anti-Obesity Medicines Strategic Design of Triple GLP-1R/GCGR/GIPR

Pain that reaches the back, pain under the right ribs, fever, yellow skin, clay-colored stool, or ongoing vomiting deserves prompt medical review

More information on this in my FDA Matters column at: Bipartisan group in Congress agrees there is no place for substandard, unregulated medicines.

The implementation of this non-invasive tool may help reduce risks to patients and potentially prevent unnecessary surgical cancellations in GLP-1RA users

American Journal of Physiology - Endocrinology And Metabolism

Small and medium manufacturers are most vulnerable, lacking the capacity to absorb these costs or pass them on due to price controls